NCT02536313 - Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2015

Primary Completion Date

March 28, 2016

Study Completion Date

June 28, 2016

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL/VOX

400/100/100 mg FDC tablet administered orally once daily with food

DRUG

RBV

Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (1)

78215

The Texas Liver Institute, San Antonio